Department of Radiation Oncology, Tenon Hospital, Assistance Publique - Hôpitaux Universitaires Paris Est, University Pierre et Marie Curie Paris VI, Paris, France.
Head Neck. 2013 Dec;35(12):1683-8. doi: 10.1002/hed.23219. Epub 2013 Jan 29.
Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ).
We retrospectively reviewed 78 patients treated with the IHF2SQ regimen. Radiotherapy was administrated as 2 fractions of 3 Gy per day (days 1 and 3), during the first, third, fifth, and seventh week of treatment with concurrent platinum-based chemotherapy.
Tolerance was excellent. Forty-one patients had complete or partial response. Median overall survival (OS) was 12.9 months and median progression-free survival (PFS) was 10.3 months. One-year OS, specific survival (SS), and PFS were 58%, 71%, 51.5%, respectively. Independent predictive factors increasing the PFS were response to chemoradiotherapy, male sex, and laryngeal tumor location.
This regimen is an alternative to conventional chemoradiotherapy with good response rates and acceptable toxicity for selected patients.
不能切除的晚期头颈部鳞状细胞癌的标准治疗方法是放化疗，但对于合并其他疾病的患者，这种治疗方法可能具有毒性。我们报告了我们使用低分割放疗方案 Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ) 的经验。
我们回顾性分析了 78 例接受 IHF2SQ 方案治疗的患者。放疗采用每天 2 次 3 Gy 的分割剂量（第 1 天和第 3 天），在治疗的第一、三、五和第七周同时给予铂类为基础的化疗。
耐受性极好。41 例患者有完全或部分缓解。中位总生存期（OS）为 12.9 个月，中位无进展生存期（PFS）为 10.3 个月。1 年 OS、特异性生存（SS）和 PFS 分别为 58%、71%和 51.5%。预测 PFS 的独立因素包括放化疗反应、男性和喉肿瘤位置。
对于选定的患者，该方案是常规放化疗的一种替代方案，具有较高的缓解率和可接受的毒性。
